-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: biotechnology
BIO submits comments on Australian Senate Patent Amendment
The Australian Senate has proposed the Patent Amendment (Human Genes and Biological Materials) Bill 2010 that aims to ban ’gene patents’. From the BIO Submission to Australian Senate Legal Committee on Patent Amendment: This amendment would exclude from patent protection “any” biological material, whether a human gene or otherwise, that is substantially identical to a naturally-occuring biological material. Specifically, the amendment states that the following materials would be catergorically declared unpatentable: “biological materials including their components Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
BIO Comments to USTR on 2011 Special 301 Review
BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)
BIO’s Intellectual Property Counsels’ Committee Spring Conference and Meeting: Seattle
Over the past eight years, BIO’s semiannual IP Counsels Committee Conference has become a popular and growing event among our members’ IP and legal professionals. Our upcoming 2011 Spring IPCC Conference in Seattle, WA on April 13-15 will be an excellent opportunity for IP professionals to hear, listen, and learn about current and projected topics related to biotechnology IP. We invite you to join us in an informal, fun and informative setting to meet fellow in-house Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
BIO Supports Patent Reform Act of 2011: Press Release
BIO Supports Patent Reform Act of 2011 Bipartisan, consensus-oriented approach will strengthen nation’s patent system Washington, D.C. (January 28, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following comment on the introduction of the Patent Reform Act of 2011 (S. 23) by Senate Judiciary Committee Chairman Patrick Leahy (D-VT) earlier this week: “BIO appreciates the dedication of Chairman Leahy, Ranking Member Charles Grassley (R-IA) and the bill’s other cosponsors for their Read More >
Biotechnology and the State of the Union Address
The following was published in Politico’s Join the Debate. Politico asked “What should Obama say in the State of the Union?” Jim Greenwood Former Congressman (R-Pa.), President and CEO, Biotechnology Industry Organization : The president’s State of the Union should, rightly, focus on jobs, particularly the need to create and fill new jobs to compete in an increasing competitive global marketplace. There’s no industry that better exemplifies the promise of job creation than Read More >
